Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Up-front polytherapy for ALK-positive lung cancer

Nature Medicine volume 21, pages 974–975 (2015)Cite this article

Subjects

A new study identifies the RAS-MAPK pathway to be an Achilles' heel of EML4-ALK fusion-positive lung cancer and suggests that up-front combination therapy directed against both pathways can achieve sustained suppression of tumor growth.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Up-front concurrent inhibition of ALK and MEK leads to sustained tumor growth suppression in EML4-ALK–positive lung cancer.

Marina Corral Spence/Nature Publishing Group

References

  1. Heist, R.S. & Engelman, J.A. Cancer Cell 21, 448.e2 (2012).

    Article  Google Scholar 

  2. Camidge, D.R., Pao, W. & Sequist, L.V. Nat. Rev. Clin. Oncol. 11, 473–481 (2014).

    Article  CAS  Google Scholar 

  3. Katayama, R. et al. Clin. Cancer Res. 21, 2227–2235 (2015).

    Article  CAS  Google Scholar 

  4. Hrustanovic, G. et al. Nat. Med. 21, 1038–1047 (2015).

    Article  CAS  Google Scholar 

  5. Hallberg, B. & Palmer, R.H. Nat. Rev. Cancer 13, 685–700 (2013).

    Article  CAS  Google Scholar 

  6. Tanizaki, J. et al. Br. J. Cancer 106, 763–767 (2012).

    Article  CAS  Google Scholar 

  7. Crystal, A.S. et al. Science 346, 1480–1486 (2014).

    Article  CAS  Google Scholar 

  8. Samatar, A.A. & Poulikakos, P. Nat. Rev. Drug Discov. 13, 928–942 (2014).

    Article  CAS  Google Scholar 

  9. Wilson, F.H. et al. Cancer Cell 27, 397–408 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bingying Zhou is in the Department of Pharmacology and the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.,

    Bingying Zhou

  2. Adrienne D. Cox is in the Departments of Pharmacology and Radiation Oncology and the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.,

    Adrienne D Cox

Authors
  1. Bingying Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrienne D Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrienne D Cox.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, B., Cox, A. Up-front polytherapy for ALK-positive lung cancer. Nat Med 21, 974–975 (2015). https://doi.org/10.1038/nm.3942

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3942

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer